Peripheral TREM2 mRNA levels in early and late-onset Alzheimer disease's patients

Gamze Guven1, Basar Bilgic2, Bedia Samanci2

  • 1Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey. gguven@istanbul.edu.tr.

Insights

Triggering receptor expressed on myeloid cells 2 (TREM2) mRNA levels are higher in late-onset Alzheimer

Area of Science:

  • Neuroscience
  • Genetics
  • Immunology

Background:

  • Triggering receptor expressed on myeloid cells 2 (TREM2) is implicated in Alzheimer's disease (AD).
  • TREM2 mRNA expression elevates in the peripheral blood of AD patients.
  • Investigating TREM2 in different AD onset types and its relation to APOE ε4 is crucial.

Purpose of the Study:

  • To compare TREM2 mRNA expression in early-onset AD (EOAD) versus late-onset AD (LOAD) patients.
  • To determine the influence of the APOE ε4 allele on TREM2 expression in AD.
  • To explore the relationship between age and TREM2 expression in AD.

Main Methods:

  • Quantitative real-time polymerase chain reaction (qPCR) was used.
  • TREM2 mRNA levels were analyzed in 30 EOAD patients, 38 LOAD patients, and age-matched controls.
  • APOE ε4 carrier status was assessed.

Main Results:

  • TREM2 mRNA levels were significantly higher in LOAD patients compared to EOAD patients.
  • Elderly controls showed higher TREM2 levels than young controls.
  • APOE ε4 carriers with LOAD exhibited elevated TREM2 expression compared to non-carriers and elderly controls.
  • TREM2 mRNA expression correlated positively with age.

Conclusions:

  • Age-related increases in TREM2 expression may contribute to differential expression between EOAD and LOAD.
  • In LOAD, advanced age and APOE ε4 allele presence synergistically elevate TREM2 expression.
  • TREM2 and APOE ε4 may interact in the pathogenesis of LOAD.